メルク株式会社ライフサイエンス（シグマ アルドリッチ ジャパン合同会社） List of News Articles

In October 2026, a new Bio-Processing Production Center will open in Deajeon, South Korea, as a new production base. This will allow us to deliver reliable biotechnology products that meet the same product specifications, performance, and quality standards as before, from a location closer to our customers, and to provide local support when needed. You will have the opportunity to try free samples. - Aseptic sampling system NovaSeptum GO - Process solutions and buffers (including CIP solutions and defoamers) - Small-scale custom media, plate media, additives, and backup services for pre-GMP manufacturing - imMEDIA ADVANTAGE - Cell culture media and feed media (dry powder and liquid, catalog products and custom-made)

Lecture Theme: Practical Strategies for Next-Generation Bio-Manufacturing - Merck's Latest Downstream Solutions - Date: November 17, 2026 (Tuesday) Time: 14:00~ (Available for on-demand viewing) Duration: 2 hours <Webinar Overview> The BioPhorum Technology Roadmap 2.0 presents the high efficiency, process integration, and expansion of single-use technologies in downstream processes as common industry priorities. In this webinar, we will introduce four of Merck's latest solutions to overcome these challenges. We will explain how these technologies contribute to achieving the future of biopharmaceutical manufacturing as outlined in the Technology Roadmap. <Key Topics> - Future of bioprocessing in the BioPhorum Technology Roadmap 2.0 - Challenges in downstream processes and Merck's latest solutions *We sincerely apologize, but participation from other companies in the same industry and those not involved in pharmaceutical manufacturing is not permitted. Thank you for your understanding.*

At Merck, we have been holding gene therapy pharmaceutical seminars approximately every two years, but we have received requests from everyone to hold them once a year. Furthermore, in recent years, the development of gene therapies in Japan has accelerated, and ONODERA GT Pharma is conducting multiple clinical trials of Japan-origin AAV pharmaceuticals, including those in the application preparation stage. Against this backdrop, we hope to further invigorate the development of AAV pharmaceuticals in Japan and have decided to co-host an AAV forum with ONODERA GT Pharma. In this forum, ONODERA GT Pharma will introduce AAV development, provide regulatory updates, and discuss AAV CMC development topics. Merck will present new manufacturing technologies and testing services for clinical trials. After the presentations, a lab tour of ONODERA GT Pharma is also planned. Additionally, we are planning to hold a panel discussion and an information exchange meeting, hoping to create a space for exchanging opinions and networking.